Insulet price target raised to $317 from $234 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Insulet (PODD) to $317 from $234 and keeps an Overweight rating on the shares. Insulet “had a strong 3Q print,” says the analyst, who cites “high quality growth, strong cash flow characteristics, and catalysts on the horizon” for the firm’s higher target following the company’s quarterly report.